Food allergy is one of the most prevalent chronic non-infectious diseases globally, with an increasing incidence.In 2024, the European Academy of Allergy and Clinical Immunology published guidelines on the management of immunoglobulin E-mediated food allergy.The guidelines employ the Grading of Recommendations Assessment, Development, and Evaluation evaluation system and put forth 14 recommendations pertaining to 5 key areas: dietary intervention, psychological support, management plans, allergen-specific immunotherapy, and biological agents.This article interprets the guidelines from the perspective of strength, reasons, and practical significance.The aim is to provide a reference for clinical work and to improve the level of management of food allergies.

The incidence of food allergy is on the rise, with the capacity to impact various organ systems, including but not limited to the skin, respiratory system, gastrointestinal system, cardiovascular system, and nervous system.In extreme cases, these allergies can result in anaphylaxis.Immunoglobulin E (IgE)-mediated type Ⅰ hypersensitivity reactions are a common cause of food allergy and are the primary pathway to anaphylaxis.Omalizumab, the first biologic therapy approved for the treatment of IgE-mediated food allergy, can be incorporated into a comprehensive management strategy for food allergy sufferers.However, due to the lack of definitive evidence, the safety and efficacy of Omalizumab in all patients with IgE-mediated food allergy remain equivocal.In light of this, Global Allergy and Asthma European Network Anaphylaxis Centres of Reference and Excellence convened a panel of experts to deliberate on the appropriate patient and therapeutic strategies for Omalizumab, culminating in a consensus statement.This paper aimed to interpret the consensus proposed by the experts, with the objective of assisting clinicians in better understanding the application of Omazumab in patients with IgE-mediated food allergy.

" Guidelines for the diagnosis and optimal management of asthma in children (patient and public version, 2025)" is the first asthma management guideline specifically designed for patients and the general public in China.It addresses 30 core issues related to the concept, diagnosis, staging and grading, treatment, management, prevention and education of pediatric asthma.The guideline emphasizes the importance of individualized and long-term management, highlights the crucial role of self-management, and stresses the need for multidisciplinary collaboration to achieve simultaneous management of asthma and its comorbidities.It covers the entire cycle from prevention in infancy to transition management in adolescence, ensuring that patients receive continuous and effective medical support at different stages.This guideline aims to enhance the understanding of asthma among patients and the public, improve compliance with standardized diagnosis and treatment, and contribute to achieving pediatric asthma prevention and treatment goals.

The Global Initiative for Asthma (GINA) 2025 has conducted a comprehensive revision of the diagnosis and management of asthma in children aged 5 years and younger.The most important update is the first-time proposal of the specific conditions for asthma diagnosis in this age group.This article aims to interpret the relevant content of diagnosis, exacerbation management, assessment and treatment of asthma in children aged 5 years and younger in GINA 2025.It is hoped that this will provide a reference for clinical practice and enhance the management of asthma in children aged 5 years and younger.

The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.

Food allergy is one of the most prevalent chronic non-infectious diseases globally, with an increasing incidence.In 2024, the European Academy of Allergy and Clinical Immunology published guidelines on the management of immunoglobulin E-mediated food allergy.The guidelines employ the Grading of Recommendations Assessment, Development, and Evaluation evaluation system and put forth 14 recommendations pertaining to 5 key areas: dietary intervention, psychological support, management plans, allergen-specific immunotherapy, and biological agents.This article interprets the guidelines from the perspective of strength, reasons, and practical significance.The aim is to provide a reference for clinical work and to improve the level of management of food allergies.

The incidence of food allergy is on the rise, with the capacity to impact various organ systems, including but not limited to the skin, respiratory system, gastrointestinal system, cardiovascular system, and nervous system.In extreme cases, these allergies can result in anaphylaxis.Immunoglobulin E (IgE)-mediated type Ⅰ hypersensitivity reactions are a common cause of food allergy and are the primary pathway to anaphylaxis.Omalizumab, the first biologic therapy approved for the treatment of IgE-mediated food allergy, can be incorporated into a comprehensive management strategy for food allergy sufferers.However, due to the lack of definitive evidence, the safety and efficacy of Omalizumab in all patients with IgE-mediated food allergy remain equivocal.In light of this, Global Allergy and Asthma European Network Anaphylaxis Centres of Reference and Excellence convened a panel of experts to deliberate on the appropriate patient and therapeutic strategies for Omalizumab, culminating in a consensus statement.This paper aimed to interpret the consensus proposed by the experts, with the objective of assisting clinicians in better understanding the application of Omazumab in patients with IgE-mediated food allergy.

" Guidelines for the diagnosis and optimal management of asthma in children (patient and public version, 2025)" is the first asthma management guideline specifically designed for patients and the general public in China.It addresses 30 core issues related to the concept, diagnosis, staging and grading, treatment, management, prevention and education of pediatric asthma.The guideline emphasizes the importance of individualized and long-term management, highlights the crucial role of self-management, and stresses the need for multidisciplinary collaboration to achieve simultaneous management of asthma and its comorbidities.It covers the entire cycle from prevention in infancy to transition management in adolescence, ensuring that patients receive continuous and effective medical support at different stages.This guideline aims to enhance the understanding of asthma among patients and the public, improve compliance with standardized diagnosis and treatment, and contribute to achieving pediatric asthma prevention and treatment goals.

The Global Initiative for Asthma (GINA) 2025 has conducted a comprehensive revision of the diagnosis and management of asthma in children aged 5 years and younger.The most important update is the first-time proposal of the specific conditions for asthma diagnosis in this age group.This article aims to interpret the relevant content of diagnosis, exacerbation management, assessment and treatment of asthma in children aged 5 years and younger in GINA 2025.It is hoped that this will provide a reference for clinical practice and enhance the management of asthma in children aged 5 years and younger.

The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.